On Thursday, Omnicom Group Inc. (NYSE:OMC)’s shares inclined 0.15% to $73.11.
The Integer Group, a global leader in promotional, retail and shopper marketing, declared recently that it has opened an office in Atlanta, Georgia at One Alliance Center in Buckhead. The Atlanta office will focus on retail design, merchandising, technology and integration.
Headquartered in Denver, Colorado, The Integer Group is a retail-marketing agency with over 1,000 employees, 7 U.S. offices, and 19 international offices. The Omnicom Group is one of the largest communication and marketing agency netoperates in the world, representing over 1,500 agencies and 5,000 brands in more than 100 countries.
Omnicom Group Inc., together with its auxiliaries, operates as an advertising, marketing, and corporate communications services company in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It offers services in advertising, customer relationship administration, public relations, and specialty communications areas.
Violin Memory Inc (NYSE:VMEM)’s shares dropped -7.30% to $2.16.
Violin Memory®, Inc., (VMEM) a global pioneer of award-winning flash storage platform solutions for primary storage and active workloads, declared its All-Flash Array solutions were selected by arvato Systems, a global next generation IT systems integrator, focused on “Digital Transformation Solutions.” arvato Systems integrated Violin all-flash solutions to streamline the company’s storage and data centre infrastructure and enhance performance for business-critical applications, counting customer relationship administration (CRM) and supply chain administration (SCM).
Violin Memory, Inc. develops and supplies memory-based storage systems to bring storage performance in line with high-speed applications, servers, and networks worldwide. The company provides flash storage platforms and all flash arrays that integrate enterprise-class hardware and software technologies to address the limitations of hard disk drive-based and solid state drive-based storage solutions that use off-the-shelf components.
At the end of Thursday’s trade, Anthera Pharmaceuticals Inc (NASDAQ:ANTH)‘s shares surged 2.72% to $9.82.
Anthera Pharmaceuticals, Inc. (ANTH) declared financial results and an operational update for the second quarter ended June 30, 2015.
Net loss for the quarter and six months ended June 30, 2015 was $8.9 million and $16.6 million, respectively, contrast to $7.3 million and $15.2 million for the corresponding periods in 2014. The enhance in net loss both quarterly and year-to-date is mainly driven by higher clinical development expense for our blisibimod program and manufacturing and study preparation expenses for the Sollpura(TM) development program. The enhance in operating expense both quarterly and year-to-date is offset by revenues of $0.3 million and $0.5 million in connection with the amortization of license fee and FTE reimbursement from our collaborative partner, and $0.4 million and $0.9 million in cost share reimbursement from our partner. Furthermore, operating expense is reduced by $1.1 million in connection with our achievement of certain milestones specified in a research award granted to us by the Cystic Fibrosis Foundation Therapeutics (“CFFT”) for the development of Sollpura(TM). Comprised of in operating expense are $0.7 million and $1.2 million of non-cash stock-based compensation recorded for the three and six months ended June 30, 2015, contrast to $0.5 million and $1.3 million in the corresponding periods in 2014.
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for patients with unmet medical needs. It is developing blisibimod, a Phase III product candidate that targets B-cell activating factor associated with various B-cell mediated autoimmune diseases, counting systemic lupus erythematosus, Immunoglobulin A nephropathy, lupus nephritis, and others.
PTC Therapeutics, Inc. (NASDAQ:PTCT), ended its Thursday’s trading session with -3.31% loss, and closed at $37.72.
PTC Therapeutics, Inc. (PTCT) declared the appointment of Glenn D. Steele Jr., M.D., Ph.D. to the company’s Board of Directors. Dr. Steele served as President and Chief Executive Officer of Geisinger Health from March 2001 until May 2015 and is now Chairman of xG Health Solutions, a Geisinger spinoff.
Dr Steele formerly served as the dean of the Biological Sciences Division and the Pritzker School of Medicine and vice president for medical affairs at the University of Chicago, in addition to the Richard T. Crane Professor in the Department of Surgery. Prior to that, he was the William V. McDermott Professor of Surgery at Harvard Medical School, President and Chief Executive Officer of Deaconess Professional Practice Group and chairman of the department of surgery at New England Deaconess Hospital in Boston. Dr. Steele serves on the board of directors of several public companies, counting, CEPHEID, Weis Markets Inc., and Wellcare Health Plans Inc. In addition, Dr. Steele serves on the governing body of several private organizations, counting Bucknell University, xG Health Solutions, and Geisinger Health System.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The company’s lead product is Translarna (ataluren), which is in Phase III clinical trials for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and for the treatment of cystic fibrosis caused by nonsense mutations. It also intends to develop Translarna for the treatment of mucopolysaccharidosis type I caused by nonsense mutation, in addition to develops spinal muscular atrophy, which is in Phase II clinical program.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.